Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

MacroGenics, Inc. (MGNX)

5.92   -0.25 (-4.05%) 11-25 13:00
Open: 5.96 Pre. Close: 6.17
High: 6.1 Low: 5.63
Volume: 722,919 Market Cap: 364(M)

Technical analysis

as of: 2022-11-25 1:58:45 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 8.84     One year: 10.32
Support: Support1: 5.33    Support2: 3.96
Resistance: Resistance1: 7.57    Resistance2: 8.84
Pivot: 6.39
Moving Average: MA(5): 6.22     MA(20): 6.04
MA(100): 4.3     MA(250): 7.17
MACD: MACD(12,26): 0.4     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 47.2     %D(3): 52.7
RSI: RSI(14): 53.8
52-week: High: 18.25  Low: 2.13
Average Vol(K): 3-Month: 900 (K)  10-Days: 1,266 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MGNX ] has closed above bottom band by 10.8%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.36 - 6.42 6.42 - 6.45
Low: 5.71 - 5.78 5.78 - 5.83
Close: 6.08 - 6.21 6.21 - 6.29

Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Headline News

Fri, 25 Nov 2022
Will MacroGenics Inc (MGNX) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Wed, 23 Nov 2022
Expert Ratings for Macrogenics - Macrogenics (NASDAQ:MGNX) - Benzinga

Thu, 17 Nov 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab -

Tue, 15 Nov 2022
BMO Capital Markets has upgraded MacroGenics (NASDAQ:MGNX) to "Outperform." - Best Stocks

Mon, 14 Nov 2022
Why MacroGenics Stock Crushed the Market on Monday - Nasdaq

Mon, 07 Nov 2022
Analyst Ratings for Macrogenics - Macrogenics (NASDAQ:MGNX) - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 50 (M)
% Held by Insiders 2.5 (%)
% Held by Institutions 96 (%)
Shares Short 5,070 (K)
Shares Short P.Month 4,960 (K)

Stock Financials

EPS -3.56
EPS Est Next Qtl -1.11
EPS Est This Year -4.41
EPS Est Next Year -3.99
Book Value (p.s.) 2
Profit Margin (%) -205
Operating Margin (%) -206.1
Return on Assets (ttm) -40.8
Return on Equity (ttm) -92
Qtrly Rev. Growth 166.5
Gross Profit (p.s.) -2.28
Sales Per Share 1.51
EBITDA (p.s.) -2.93
Qtrly Earnings Growth 0
Operating Cash Flow -171 (M)
Levered Free Cash Flow -99 (M)

Stock Valuations

PE Ratio -1.67
PEG Ratio 0
Price to Book value 2.96
Price to Sales 3.91
Price to Cash Flow -2.14

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.